Heidelberg Pharma AG to Raise Capital in a Private Placement

Heidelberg Pharma AG / Key word(s): Financing
Heidelberg Pharma AG to Raise Capital in a Private Placement

15-Jun-2021 / 18:28 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.

Ad hoc announcement - Inside information pursuant to Article 17 MAR

Heidelberg Pharma AG to Raise Capital in a Private Placement

Ladenburg, Germany, 15 June 2021 - The Executive Management Board of Heidelberg Pharma (FSE: HPHA) today adopted a resolution, with the approval of the Supervisory Board, to launch a private placement of new shares to institutional investors in Europe and the US via an accelerated book building transaction. DH-LT-Investments GmbH, St. Leon-Rot, Germany, an investment company of Mr. Dietmar Hopp, will participate in the capital increase. The main shareholder of Heidelberg Pharma is dievini Hopp Biotech holding GmbH & Co. KG, Walldorf, Germany.

Heidelberg Pharma will offer up to 3,106,637 new no-par value bearer shares, or up to 10% of the registered share capital, using authorized capital and excluding shareholders' preemptive rights, thereby increasing its share capital from EUR 31,066,372.00 to up to EUR 34,173,009.00. The new shares are expected to be admitted to listing on the Frankfurt Stock Exchange following their issuance.

Book building will commence immediately. It is anticipated that books will close on 15 June 2021 in the evening, although the Sole Global Coordinator reserves the right to close the books at any time.

Heidelberg Pharma AG plans to use the expected total gross proceeds from the capital increase to secure the further development of the proprietary ATAC (Antibody Targeted Amanitin Conjugates) pipeline candidates and the ATAC technology, in particular the clinical development of the proprietary lead candidate HDP-101.

Bryan, Garnier & Co, acting as Sole Global Coordinator and Sole Bookrunner, will execute the capital increase.

+++ End of the ad hoc announcement +++

Important notes/Disclaimer

This communication does not constitute or form part of an offer of securities for sale or solicitation of an offer to purchase securities in the United States, Canada, Australia, Japan or in any other jurisdiction in which such offer may be restricted. The securities referred to in this communication have not been, and will not be, registered under the US Securities Act of 1933, as amended (the 'Securities Act'), and may not be offered or sold in the United States, except on the basis of an applicable exemption from registration or in a transaction not subject to registration under the Securities Act. There will be no public offering of securities in the United States or anywhere else.

In the United Kingdom, this communication is directed only at persons who: (i) are qualified investors within the meaning of the Financial Services and Markets Act 2000 (as amended) and any relevant implementing measures and/or (ii) are outside the United Kingdom or (iii) have professional experience in matters relating to investments and fall within the definition of 'investment professionals' contained in article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the 'Order') or are persons falling within article 49 (2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as 'Relevant Persons'). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

About Heidelberg Pharma

Heidelberg Pharma AG is an oncology company and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company's own therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma and will enter clinical development shortly. HDP-102, a CD37 ATAC for Non-Hodgkin's lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'will' 'should' 'future', 'potential' or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

15-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de